An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

Trial Profile

An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs VB10.16 (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; First in man
  • Sponsors Vaccibody
  • Most Recent Events

    • 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Feb 2018 According to a PharmaJet media release, Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis needle-free injection system.
    • 12 Dec 2017 According to a Vaccibody media release, 6 months results from this study is anticipate in Q3 2018, and final results are anticipate in Q1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top